Moderna, Inc.

MRNA

161
'Ticker: MRNA

Direction: Up

Prognosis: Buy Calls (Author bought $40 and $41 calls expiring this week, considering rolling to later dates)

Reasoning: New Covid-like virus discovered, rising avian flu concerns, large institutional buying, bullish technical indicators (RSI divergence, MACD turning up), high call option volume and open interest. Author acknowledges that a drop below $30 could invalidate the thesis.

Disclaimer: This is not financial advice. MRNA is volatile; know your risk tolerance.

Bonus: Author also mentions potential plays on HD puts, LOW puts, and CLF calls.'

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。